The development of cytosolic 5'-nucleotidase II (cN-II) inhibitors is essential to validate cN-II as a potential target for the reversion of resistance to cytotoxic nucleoside analogues.
INTRODUCTION
5'-nucleotidases (EC 3.1.3.5) are a family of enzymes that catalyze the hydrolysis of 5'-nucleoside monophosphates (5'-nucleotides) into their corresponding parent nucleosides and inorganic phosphate, and thereby play a key role in the metabolism of nucleotides. The membrane-bound ecto-5'-nucleotidase, CD73, is mainly responsible for the conversion of extracellular adenosine 5'monophopshate (AMP) into adenosine, whereas intracellular 5'-nucleotidases (cN-I, cN-II, cN-III, cdN, mdN) regulate the intracellular pools of both purine-and pyrimidine-based 5'-nucleotides and nucleosides, depending on their substrate specificity and intracellular compartments [1] [2] . cN-IA uses both AMP and pyrimidines and is expressed in muscles, whereas its homologue cN-IB is AMP specific and ubiquitously expressed. The cytosolic cN-II and cN-IIIA are GMP/IMP and pyrimidine preferring, respectively. cN-II is ubiquitously expressed and at a higher level in highly proliferating cells, whereas cN-IIIB is important in erythrocytes but has also been found in many other tissues.
More recently, a cN-IIIB was described and found to be specific to 7-methyl-GMP [3] . Finally, the cytosolic cdN and the mitochondrial mdN are active on deoxyribonucleosides phosphorylated on 3' or 5', with a preference towards pyrimidine derivatives.
Several studies have shown that deficiencies of these proteins are associated to severe diseases. For example, deficiency in cN-III due to genetic mutations leads to hemolytic anemia [4] , CD73 deficiency is associated to arterial calcification [5] , and the NT5C2 (coding for cN-II) containing locus has been associated with autosomal recessive spastic paraplegia and psychiatric disorders [6] [7] [8] . In addition, high expression level or activity of cN-II in tumor cells is associated with resistance to cytotoxic nucleoside analogues and nucleobases [9] [10] [11] . Its direct role in this resistance was shown by the sensitization of human cancer cells to purine nucleoside analogues after inhibition of its expression by shRNA [12] . Based on these observations, cN-II represents an attractive target to inhibitors and taking into account that cN-II is also named high-KM 5'-nucleotidase, it is not surprising to observe such high Ki values (KM for inosine 5'-monophosphate (IMP) is ~ 0.5 mM).
Despite this, co-exposure of cancer cells to nucleoside analogues and some of these cN-II inhibitors potentiated the effect of cytotoxic nucleoside analogues [14, 15] . Herein, we pursue the development of cN-II inhibitors using a small set of fragment hits, which have been previously selected by a FBDD approach [19] , to build up a virtual library. The latter was generated using the Ilib-diverse software (http://www.inteligand.com), and involved the random association of various fragments and chemical groups in order to enhance binding affinity and/or retain drug-like properties such as water solubility. These in silico approaches have been successfully applied to the design of potential lead compounds such as creatine kinase [20] and phospholipase [21] inhibitors. In silico virtual screening was performed on the basis of experimental cN-II crystal structures [22] and compounds with the most favorable docking scores were carefully analyzed.
Thus, one derivative was hand-picked to guide structural optimization, on the basis of its resemblance with a previously identified inhibitor.
RESULTS AND DISCUSSION
In silico drug design, library generation and selection process. We combined in silico drug design approaches including virtual library generation followed by in silico screening by molecular docking to identify potential inhibitors [23, 24] . Briefly, virtual flasks containing the most active fragments previously identified by nuclear magnetic resonance (NMR) screening and measurement of the inhibition of the enzyme activity in vitro [19] , were used for the combinatorial generation of novel chemical scaffolds. An overview of the process is presented in Figure 2 . Flask 1 contained 21 fragments, whereas flasks 2 and 3 contained 15 fragments each (structures of the components are listed in table S1 and mainly include aromatic and bicyclic derivatives, nitrogen-containing heterocycles such as benzimidazoles, purines…). Finally, flask 4 contained 43 polar or ionisable building blocks (alcohols, carboxylic acids, phosphoesters…, see Table S1 ) available from the Ilibdiverse software. The Ilib-diverse tool generated a focused virtual library by using a Monte-Carlo-based random fragment connection including general rules of chemical synthesis feasibility. During this process, the software is randomly selecting fragments from each flask and generates molecules with a broad molecular diversity. In our setup, we defined a higher importance for experimentally validated hit fragments (cN-II binders identified by NMR) meaning that the frequency of insertion of these fragments in the final library will be higher compared to the low-active fragments (underlined fragments in Table S1 ). To further increase the diversity and also to improve the aqueous solubility of compounds, combination of one fragment taken from each of the three flasks was followed by the addition of a fourth ionisable chemical group (building blocks already included in the program that can be also considered as a fourth flask). Thus, a total of 3,000 compounds was generated (Ilibdiverse virtual library), all meeting the criteria of orally-delivered drug like compounds according to
Lipinski's rule of five (one exception was the molecular weight with an upper limit at 600 Da instead of 500 Da). Then, all compounds were evaluated by molecular docking on cN-II. The ones showing a lower score than that of our previously identified lead compound ( Fig. 1, UA2132) and hitherto most potent cN-II inhibitor reported were discarded, leaving a total of 884 compounds for further consideration. To narrow the number of molecules to be further examined for synthetic accessibility, we focused on compounds with highest docking scores (using a cut-off value of 125, which is approximately 20 points above the docking score of UA2132) resulting in a selection of 25 chemical structures (Table S2 ).
The analysis of structure similarity and fragments composition of these 25 selected hits indicates that some skeletons were privileged during the library generation and filtering process. Indeed, numerous assemblies consisting of polycyclic aromatic structures linked to a phenyl or biphenyl fragment were found to promote a favorable binding according to the docking results. Among these, one derivative particularly attracted our attention ( Fig. 3B , Ilib-72) due to its structural similarity with the previously identified cN-II inhibitor UA2132 (Fig. 3A ). In addition, several hit compounds with docking scores being slightly lower than our cut-off value (125) were identified as structural analogues of UA2132 or at least holding an adenine moiety linked to an aromatic cycle through an amide link (see Table S2 , hits highlighted in bold characters). Therefore, instead of performing the chemical synthesis of all 25 best-ranked hit compounds, we prioritized the structure optimization of our lead compound considering the structural variations observed in Ilib-72 as it was the best-ranked analogue of UA2132.
In this respect, molecular docking studies were performed to predict and compare the potential binding modes of Ilib-72 with UA2132. Since UA2132 is a competitive inhibitor, the docking of hit compounds was achieved in the substrate binding site ( Fig. 4 ). One should note that the crystal structure used for modelling (PDB 2XCW) was an inactive mutant in which one of the catalytic residues D52 was mutated to N.
Compared to other crystal structures, this mutation does not change the coordination of Mg 2+ ion (hexa-coordinated with D/N52, D54, D351, 2 water molecules and one phosphate oxygen from IMP). This mutation was used by Wallden and colleagues in order to prevent substrate hydrolysis during crystallization, thereby giving an image of the position of the substrate [25] . Similar docking poses have been obtained using the wild-type enzyme (2JC9). For UA2132, the prediction suggests only one binding mode with the adenine moiety near the catalytic residues which interact with the magnesium ion (the two first via coordination bonds and the latter via a water molecule). In contrast to UA2132, two binding orientations were predicted for Ilib-72 ( Fig. 4A & 4B ) with comparable docking scores (126.9 and 126.1). The most favorable binding mode is shown in Figure 4A with the purine and the benzyloxymethyl group near the magnesium ion. However, in the second binding mode the -hydroxyacetic acid chain is chelating the magnesium ion within a more compressed structure ( Fig. 4B ). This latter may reflect the real binding orientation of this compound since the natural substrate (IMP) also carries a negative charge on the phosphate oxygen. Interestingly, Ilib-72 occupies a large space which extends beyond the substrate binding cavity ( Fig. 4C ).
Based on this docking information, we decided to keep the N-6 biaryl substituted adenine skeleton (present in UA2132) and to add various groups either on the N-7 or N-9 position of the purine, and/or a five-membered nitrogen containing heterocycle on the biaryl moiety ( Fig. 3C and 5 ). Both substituents were chosen for their ability to either increase affinity and/or improve solubility of the final derivatives. Indeed, under physiological conditions tetrazole and phosphonate groups would be partially or completely protonated ( Fig. 5 ). regioisomers. UV absorption spectra of N-7 isomers showed slight bathochromic shifts (2-3 nm) compared to N-9 regioisomers. All these data are in agreement with data from the literature and corresponding to similar N-7 and N-9 purine isomers [26, 27] .
The synthesis of N-(phosphonomethyl) derivatives 5 (scheme 1 for N-9 adenine substitution) or 15 (scheme 2 for N-1-imidazole substitution) was performed employing diethyl ptoluenesulfonyloxymethylphosphonate as required alkylating reagent [28] . Enzymatic studies. All synthesized compounds were evaluated for their inhibitory effect against recombinant cN-II using the malachite green-based assay with quantification of inorganic phosphate produced from IMP (Tables 1-3 ) and the cLogP were calculated in order to estimate the impact of the various modifications on aqueous solubility, in comparison to UA2132 used as a reference.
When introducing modifications in the N-7 position (Table 1) , no real improvement of the inhibitory effect could be observed (1a, 2a, 6a, 6b, and 7a) as compared to UA2132. An equivalent inhibition was observed at 200 µM for derivatives 6a and 7a which were substituted at the N-7 position either by a benzyl or benzyloxymethyl group. This may be explained by a different orientation adopted by these derivatives in the binding site when compared to the compounds with N-9 modifications. Substitutions on the N-9 position of the purine heterocycle by aromatic substituents was found to reduce the activity of several compounds (6b and 7b), whereas small and linear substituents (ethyl chain for 8 and 11 or methylcarboxylate 9 and 12, or methylphosphonate 10 and 13) increased the inhibition of the enzyme. Indeed, for the best inhibitors in this series (>60% at 200 µM) substitutions were including a carboxylic (12) or a phosphonate (13) group, especially when the negative charge was unmasked. Indeed, the presence of a carboxylate or a phosphonate group is expected to increase the overall aqueous solubility as anticipated (cf. cLogP). The presence of a biphenyl moiety was mandatory for the inhibition since smaller compounds lacking this group were almost-or fully inactive (1b, 2b, and 3).
In addition, substitution of the biphenyl moiety by a five-membered ring seems to play a major role as shown by the derivative 18 incorporating an imidazole and a (monoethyl)-methylphosphonate group (without any modification in N-7 or N-9, derivative 19 was less efficient than 18).
Surprisingly, the fully unprotected compound 20 (with the closest similarity with Ilib-72) did not inhibit cN-II activity suggesting that the negative charges affect the binding mode of this compound (Table 2 ). According to the enzymatic inhibition, compound 18 appeared more advantageous (75% at 200 µM) and this may be explained by the partial negative charge compared to a fully charged compound 20 (harboring a double negative charge). *clogP values were calculated with MolInspiration (freely available online software: http://www.molinspiration.com/cgi-bin/properties) **Data for UA2132 are from [19] . n.a. when precipitation occurs upon addition of the green malachite reagent. Compounds promoting significant enzyme inhibition are indicated in bold. *** Compound 7a was 81.8% pure. 
60 ± 5%
Compounds promoting significant enzyme inhibition are indicated in bold *clogP values were calculated with MolInspiration (freely available online software: http://www.molinspiration.com/cgi-bin/properties) Finally, tetrazolo derivative 24c (and to a lower extend 24b) was a good mimicry of carboxylate group, when introduced in the meta or para orientation, confirming the improvement observed with a carboxylate group which promotes an increased solubility of these compounds associated with an enhanced activity (Table 3 ). According to the position of the tetrazolo group (ortho, meta or para regarding to the biaryl group), there was a large difference in terms of enzymatic inhibition. The most favorable substitution was in the para position (24c) followed by meta with less efficiency (24b). were further studied to determine inhibition constants and mode of inhibition. They both exhibited Ki in the sub-millimolar range, respectively 0.84 and 0.58 mM ( Fig. 6 ) and were found as competitive inhibitors ( Figure S1 ). In addition, they appeared as potent as our reference compound UA2132 (Ki =0.89 mM) with a slight advantage for 18 which is very close to the Ilib-72 chemical structure.
[IMP] (mM) Figure 7 ). Of the various studied crystal structures (Table S3) [15, 22, 25] whereas it was visible in the electron density of form II crystals [19] .
When taking the data from the previous enzyme kinetic studies into account, one cannot exclude binding of the other flexible parts of the enzyme for the other molecules for which electron density is lacking, at least for 2a, 13 and 18 for which no crystals could be obtained by co-crystallization in either forms. purple the active site [22] , in orange the "AdiS" binding site, [15] in dark blue effector site 1 and in yellow effector site 2 [25] , in wheat the "2c" site and in pink spanning over a longer range the "3c" binding site [19] .
Binding mode prediction to understand the inhibition mechanism. As no crystal structure with a ligand bound in an unequivocal manner could be obtained, molecular docking was used to understand the mechanism by which the most efficient compounds inhibit the enzyme. Compounds 12 and 13 exhibit very similar binding modes as predicted by docking ( Fig. 8A ). Both compounds were found superimposed in the active site with the carboxylic or phosphoric acid chain pointing towards the magnesium ion. This prediction cannot explain the difference in terms of enzymatic inhibition (Ki of 0.84 and 2.4 mM, respectively). However, the docking score was a good indication of the binding strength with 112.6 versus 145.9 for the carboxylic acid group and the phosphoric acid chain, respectively. This stronger theoretical binding affinity for derivative 13 can be easily explained by the overall negative charge of the compound (-2) and it should have been predicted as a better inhibitor. However, and according to the inhibition values, the inhibition efficiency seems to be governed by a more complicated mechanism. One can imagine that the higher water solubility of compound 13 may prevent or limit the access to the target binding site as the surrounding residues are aromatic (F157, H209 and Y210) and also because best inhibitors were highly hydrophobic.
When comparing their binding mode with Ilib72 (Fig. 8B ), no obvious similarity was observed with a large shift of the biaryl moiety likely due to the differential positioning of the negative charge on these compounds.
In contrast to compounds 12 and 13, the overlay between Ilib-72 and 18 or 20 (Fig. 8C ) showed is making only hydrogen bonds with N158 and T155.
Concerning derivatives 24a-e incorporating a tetrazole group, their binding orientation seems to be governed by this group. Indeed, its interaction with the magnesium ion is thought to be strong and the orientation of the rest of the molecule will depend on the ortho, meta or para position of this substituent on the biaryl skeleton ( Fig. 9A) . Indeed, the five derivatives were predicted with the tetrazolo group near the metallic ion with various orientation of the adenine moiety depending on biaryl substitution. According to the docking predictions, compounds 24a, 24d and 24e bind to the enzyme in a complete different manner, which may indicate a large variation in their binding affinity. Attempting to explain the higher efficacy of compound 24c compared to 24b (Fig. 9B ), a similar hypothesis as previously expressed for compounds 18 and 20 can be postulated with the implication of water molecules reinforcing the interactions between protein amino acids and the inhibitor (Fig. 9B ). In vitro biological evaluation. The effect of the newly synthesized compounds was evaluated on the survival of different human cancer cell lines using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) based colorimetric assay (Table S4) . IC50 values ranged from 36 µM to >300 µM, similarly as for compounds previously reported [19] . Intrinsic antiproliferative activity allowed us to perform synergy experiments with selected compounds and purine nucleoside analogues as our hypothesis states that cN-II inhibitors would enhance the effect of cytotoxic nucleoside analogues in co-exposure conditions (Fig. 10 ). Synergy (defined as CI95<0.9) was observed with cladribine for 6a (RL and HL-60), 6b (CCRF-CEM and HL-60), 7a (RL) and 10 (RL), with clofarabine for 6a (RL), 6b (HL-60) and 7a (RL) and with fludarabine for 6a (RL and CCRF-CEM) and 6b (RL, CCRF-CEM and HL-60). The differences between the cell lines is consistent with earlier observations showing that shRNA-mediated cN-II inhibition is associated with a higher level of sensitization to purine nucleoside analogues in RL and HL-60 cells as compared to CCRF-CEM cells [10] . Thus, based on these results, 6a could be considered as a good candidate and clearly better than our previous inhibitor (UA2132). It is however noteworthy that no co-incubation experiments with non-toxic compounds were performed and could have allowed the identification of other active associations. synergistic, whereas they are additive for 0.9 < CI95 < 1.1 and antagonistic for CI95 > 1.1.
CONCLUSION
By using a combination of various in silico approaches, we designed a large chemical library of potential cN-II inhibitors with numerous different scaffolds of which some leading to inaccessible chemical synthesis. Consequently, we focused on the structural optimization of a previously characterized inhibitor that was also part of the Ilib-generated compound (Ilib-72). This allowed us to explore the chemical diversity of this lead compound in order to improve its affinity for the targeted protein and/or physico-chemical properties such as solubility. Twenty-six derivatives were synthesized, evaluated toward the purified recombinant enzyme. About ten compounds could inhibit more than 50% of the enzymatic activity at a concentration of 200 µM. In comparison with our reference compound (UA2132, a previously identified competitive inhibitor), three derivatives (12, 13 and 18) displayed similar potency, with Ki in the micromolar range and a competitive mechanism of action. All three compounds have a polar and anionic substituent (either a carboxylate or a phosphonate) and derivative 18 presented the closest structural similarity with Ilib-72, the derivative selected from the library generation and in silico screening process. Molecular modelling and X-ray crystallography studies were carried out to predict and assess the binding modes of these novel derivatives. When tested in cell culture experiments, synergistic effects were observed with all cytotoxic nucleoside analogues tested and compounds 6a-b. Some compounds had minor cytotoxicity, and their complete toxicity profile on non-cancerous cells will be needed for further development. These results are therefore encouraging to investigate further the potential of these compounds as to our knowledge they appeared as the most potent cN-II inhibitors reported to date.
EXPERIMENTAL SECTION
Library generation and molecular docking studies. Using hit fragments previously identified by NMR screening [19] , a focused library of final compounds targeting cN-II was generated using Ilibdiverse program (www.inteligand.com) by randomly assembling three different hit fragments. A weighting percentage has been attributed for the fragments that were previously identified as cN-II inhibitors (Table S1 in SI). In addition, several functional or polar groups were included to increase the solubility of the final compounds (hydroxyl, sulfonate, phosphate and phosphonate groups). This procedure allowed us to generate 3,000 compounds supposed to be chemically synthesizable (the program includes general rules of chemical synthesis during the linkage process). All derivatives were analyzed and their coordination and geometry corrected by using the VegaZZ molecular modelling program [30] . Atomic charges were assigned using the Gasteiger-Marsili empirical atomic partial charges [31] and the potential energy of all compounds was minimized using 500 steps of steepest descent followed by 5,000 steps of conjugate gradient (tolerance of 0.01 kcal/mol. Å). For compounds comprising a tetrazole group, only one tautomer has been evaluated by docking.
Molecular docking was carried out with the GOLD v5. Enzyme inhibition and steady state kinetics assays. The nucleotidase activity was measured using the Green Malachite Phosphate Assay kit (Gentaur) as previously described [16, 19] . Briefly, inhibition constants, as previously described [19] . Briefly, enzyme (alone or in presence of compounds) and substrate (IMP at different concentrations varying from 0.2 to 3 mM) were mixed in a thermostatically controlled beaker under magnetic stirring at 37 °C (same buffer as for the previous assay). Every 7 s, samples were taken from the mixture and reaction was stopped by adding 10% of perchloric acid. Quantification of IMP and inosine was performed by HPLC (Waters Alliance) using a Partisphere 5-SAX column (AIT France) and 10 mM ammonium phosphate buffer pH 5.5 as mobile phase. The raw data (IMP and inosine peaks area integrated with Empower software, Waters)
were analyzed using Grafit 7 (Erithacus Software) and fitted with equations describing either a competitive, a non-competitive, an uncompetitive or a mixed inhibition mechanism. The equation that reproduced best the experimental data was selected for the determination of the inhibition mode by also taking into account the chi square value (confidence computed from the fitting giving the independence statistical test between experimental and theoretical values).
Cell-based experiments. Cell survival in presence of cN-II inhibitors and purine nucleoside
analogues alone (intrinsic cytotoxicity) or in combination (synergy experiments) was determined with human follicular lymphoma cells (RL), human acute lymphoblastic leukemia cells (CCRF-CEM) and human acute promyelocytic leukemia cells (HL-60). as described earlier [15, 19] . Briefly, ten thousand cells were seeded per well in 96-well plates and incubated with different concentrations of drugs and inhibitors alone or in fixed ratio combinations for 72 hours, and cell survival was determined with the MTT assay. Inhibitory concentrations 50 (IC50, concentrations associated with 50% cell survival as compared to unexposed cells) and combination index 95 (CI95, a parameter for the quantification of the combinatory effect of the two compounds to achieve 95% inhibition of cell survival) were calculated with the CompuSyn software based on the Chou and Talalay method. [29] Drug combinations with CI95 < 0.9 are considered synergistic, whereas they are additive for 0.9 < CI95 < 1.1 and antagonistic for CI95 > 1.1.
Crystallization, data reduction, structure determination and refinement. Protein used for Xray crystallography studies was prepared as described earlier [34] UA2132, 2a, 7a, 12, 13, 18 and 20 to final concentrations of 5 and 10 mM of these latter and incubated at 4 C for 20 minutes prior to co-crystallization setup.
Crystals grown in the presence of compounds (co-crystallization) appeared upon 1-2 weeks. Only compounds 7a and 20 could be co-crystallized, and in forms II and I, respectively. For soaking experiments (conducted in parallel), native crystals (both forms) appeared after approximately one
week at 4 C. Only form I crystals were further studies due to an extreme fragility of form II crystals which fell apart upon soaking. For cryo-protection, crystals were transferred to a drop containing the crystallization reservoir solution (at the above mentioned conditions) supplemented with 10% and 15% glycerol for "form I" and "form II" crystals, respectively, and flash-frozen in liquid nitrogen.
Hereafter, X-ray diffraction data were collected at the European Synchrotron radiation facility (ESRF Grenoble France), and integrated and scaled using programs from the XDS package [35] . All crystal structures were determined using the molecular replacement method and the program "Phaser" [36] as implemented in the "Phenix" software suite [37] and the previously reported cN-II structures (2J2C) [22] and (5CQZ) [19] as search models for forms I and II, respectively. Refinement was performed using the programs "Refmac5" [38] and "Phenix" [37] , altering with iterative model re-building and analysis with "COOT" [39] . Ligands and water molecules displayed 2Fo-Fc and Fo-Fc electron densities contoured at the 1 and 3 level, respectively, prior to refinement. The pdb coordinates and topology of the compounds tested for binding during refinement (though lacking in final three-dimensional structures) were obtained using the PRODRG2 server [40] and the program "eLBOW" as implemented in "Phenix". Libraries for refinement of these molecules were generated using the program LIBCHECK as implemented in the CCP4 program package [41] . Composite omit maps were calculated ("Phenix") in order to reduce model bias, and rmsd's were calculated with the program TM-score [42] . Data collection and refinement statistics are given in Table S3 .
Coordinates and structure factors of the cN-II structures have been deposited at the RCSB 
Description of general methods for chemical synthesis is already published [19]
Diethyl p-toluenesulfonyloxymethylphosphonate [28] , compounds 1a-b, [43] , 2a-b [44] , 3 [45] and 4 [46] were prepared according to previously published procedures. (1-4) . To a stirred solution of adenine (7.40 mmol) in DMF (30 mL) was added under argon dry K2CO3 (10.73 mmol) and the corresponding alkyl halide (8.88 mmol). The mixture was stirred at room temperature until thin layer chromatography (TLC) revealed that the starting material was consumed. The solvent was evaporated under reduced pressure and the residue was purified on silica gel column chromatography (CH2Cl2/MeOH, 0-10%) to provide compounds 1-3 whereas compound 4 was isolated after precipitation in water and filtration. N-(7-Benzyl-7H-purin-6-yl)-[1,1'-biphenyl (11) (4-(3'-((7H-purin-6-yl) (1.5 eq.), N,N-dimethyl-4-aminopyridine (0.2 eq.), adenine or N-9 substituted adenine 4 (3 eq.). The reaction mixture was stirred at 100 °C until HPLC revealed that the starting material was consumed.
General Procedure for Synthesis of Compounds

7-Benzyl
N-(7-((Benzyloxy)methyl)-7H-purin-6-yl)-[1,1'-biphenyl]-3-carboxamide
N-(9-((Benzyloxy)methyl)-9H-purin-6-yl)-[1,1'-biphenyl]-3-carboxamide
N-(9-(2-Hydroxyethyl)-9H-purin-6-yl)-[1,1'-biphenyl]-3-carboxamide
Volatiles were removed under reduced pressure. Excess of adenine was precipitated in isopropanol, filtered off and the filtrate was evaporated. The residue was firstly purified by silica gel column chromatography (CH2Cl2/EtOH/AcOH,90/5/5, v/v/v) and then on reverse phase (RP18 using a gradient of water to methanol containing 1% AcOH) to provide the desired compounds. -tetrazol-5-yl)-[1,1'- Purin-6-yl)-3'-(2H-tetrazol-5-yl)-[1,1'- 
N-(9H-Purin-6-yl)-4'-(2H
N-(9H-
